Neuraxis reports Q2 EPS (22c) vs. (42c) last year

Reports Q2 revenue $894,000 vs. $612,000 last year. Brian Carrico, CEO of NeurAxis (NRXS) commented “We remain highly encouraged by the Company’s trajectory, with strong revenue growth anticipated in the near term following several critical achievements in recent months. Our focus continues to be on expanding insurance coverage and executing large-scale IB-Stim commercialization. In May, we completed a $5 million equity-only financing round, supported by existing and new institutional investors. This capital will enable us to execute on our growth strategy and advance our commercial efforts. We are approaching a major inflection point with national insurance coverage, as IB-Stim’s Category I CPT code is set for utilization on January 1, 2026. Additionally, we recently secured inclusion of our proprietary PENFS technology in clinical practice guidelines from leading academic societies-a significant endorsement that supports expanded access on a broader scale. We expect this expanded coverage to drive substantial revenue growth and improved gross margins, as more devices are reimbursed at full commercial rates. We also achieved a major regulatory milestone with FDA clearance to expand IB-Stim’s indication to include pediatric Functional Dyspepsia. This expansion significantly increases our total addressable market and enables us to leverage our existing provider and payer relationships. Operational performance remained strong in the second quarter, with revenue increasing 46% year-over-year and units sold rising 58%. Importantly, we are beginning to see operating leverage in the business, as operating losses declined by 22% year-over-year. Based on our strong top-line momentum and strategic positioning, we remain confident in achieving breakeven in 2026.”